Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis.
Antiepileptic drugs fail to ease irritability or global autism symptoms, so choose better-supported options first.
01Research in Context
What this study did
Hirota et al. (2014) hunted for proof that antiepileptic drugs calm irritability in kids with autism. They pulled every randomized trial they could find—only seven small studies with 171 children total. Each trial compared an antiepileptic like valproate or levetiracetam against placebo for at least two weeks.
What they found
Pooling the seven trials showed no meaningful win for the drugs. Irritability scores barely budged, and global autism severity stayed flat. Side-effects were common, but benefits were not.
How this fits with other research
Parsons et al. (2013) had already warned that most autism drug evidence is thin; Tomoya’s stricter math now proves the point for antiepileptics. Farmer et al. (2012) and Breider et al. (2024) show parent training plus or minus other meds cuts serious behavior problems, giving you a working alternative. Fovel et al. (1989) found haloperidol actually tamed symptoms, so the ‘no-effect’ verdict here is drug-specific, not a blanket ‘nothing works.’
Why it matters
If a family asks about antiepileptics for irritability, you now have clear data to say, ‘Evidence shows little benefit.’ Pivot the plan toward parent training or meds with proven track records, and save everyone time and side-effects.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Review any client on antiepileptics for irritability—flag the med team if the drug lacks a clear seizure reason.
02At a glance
03Original abstract
Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities.
Journal of autism and developmental disorders, 2014 · doi:10.1007/s10803-013-1952-2